Release Date: December 2nd, 2016
Expiration date: June 2nd, 2017
Estimated Time to Complete Activity: 1.5 hours
CME ACCREDITATION AND DESIGNATION
The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cardiovascular Research Foundation designates this activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Documentation of awarded credit is provided for participants in exchange for completed activity evaluations.
OVERVIEW
Pretreatment of patients undergoing percutaneous coronary intervention (PCI) has been controversial. The decision to use P2Y12 Inhibitors has been the cornerstone treatment of patients with acute coronary syndrome. This program will look at the correct timing and modality of transition from intravenous to oral platelet inhibition in patients. Lessons learned from the PHOENIX and CHAMPION study and the outcomes of establishing potent P2Y12 inhibition with medication will be discussed. Prevention of intra-procedural stent thrombosis and the advances of therapies will be reviewed. Completing this presentation, experts in the field will share tips to help the practitioner with the transition to oral P2Y12 receptor blockades.
AGENDA
Is Oral Agent Preloading Before PCI Safe or Effective? Theory and Evidence
C. Michael Gibson
Roundtable Discussion with Audience Q&A
Outcomes of Establishing Potent P2Y12 Receptor Inhibition with Intravenous Cangrelor: Lessons From the PHOENIX and the CHAMPION Trials
Robert A. Harrington
Roundtable Discussion with Audience Q&A
Intra-Procedural Stent Thrombosis: What Is It; Why Should We Care; and How Can We Prevent It?
Philippe Genereux
Roundtable Discussion with Audience Q&A
Transitioning From Oral to Intravenous P2Y12 Receptor Blockade, and From Intravenous to Oral P2Y12 Receptor Blockade: What the Practitioner Needs to Know
Dominick J. Angiolillo
Roundtable Discussion with Audience Q&A
Patient Selection and Adjunct Pharmacology for Potent Intravenous Platelet Inhibition: Practical Considerations
Deepak L. Bhatt
LEARNING OBJECTIVES
After participating in this event, learners will be able to:
- Discuss the advantages and concerns of oral platelet preloading before PCI
- Explain implications of recent clinical trial data related to intravenous Cangrelor
- Define intra-procedural stent thrombosis and how to prevent it
- Describe what the practitioner needs to know about transitioning from oral to intravenous P2Y12 receptor blockades and vice versa
TARGET AUDIENCE
This activity is designed for interventional cardiologists, cardiac surgeons, clinical cardiologists, vascular medicine specialists, and other health care professionals.
ACTIVITY EVALUATION
Evaluation by questionnaire will address content, presentation, possible bias, and future educational needs.
DISCLOSURE STATEMENT
It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and, therefore, does not compromise the scientific integrity of the educational activity.
Discussion of off-label product usage and/or off-label product use is made at the sole discretion of the faculty. Off-label product discussion and usage is not endorsed by the Cardiovascular Research Foundation or the conference directors of this activity.
Faculty participating in continuing medical education activities sponsored by the Cardiovascular Research Foundation are required to disclose to the activity audience any real or apparent conflicts of interest related to the content of their presentations. Faculty not complying with this policy are not permitted to participate in this activity.
DISCLOSURE SUMMARY
KEY: (G/R) Grant Support/Research Contract (C/H/S) Consultant Fee/Honoraria/Speaker’s Bureau (E) Equity (R/I) Royalty/Intellectual Property Rights (S) Salary/Salary Support (O) Other Financial Benefit
Faculty
Dominick J. Angiolillo (G/R) Glaxo Smith Kline, Eli Lilly, Daiichi-Sankyo, The Medicines Company, AstraZeneca, Janssen, Osprey Medical, Inc., Novartis, Merck, CSL Behring , Gilead (C/H/S) Bayer, Eli Lily, Daiichi Sankyo, Inc. AstraZeneca, The Medicines Company, Merck, Sanofi, PLx Pharma, Amgen
Deepak L. Bhatt (G/R) Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company
Philippe Genereux (G/R) Boston Scientific Corp., (C/H/S) Abbott, Edwards Lifesciences, Cardiovascular System Inc.
C. Michael Gibson (G/R) Angel Medical Corp., Bayer, CSL Behring, Ikaria, Janssen, J&J, Portola, Stealth Peptides, St. Jude Medical (C/H/S) Eli Lilly, Gilead, The Medicines Company, Novo Nordisk, Pfizer St. Jude Medical
Christian W. Hamm (C/H/S) AstraZeneca, Sanofi Aventis, Boerhringer Ingelheim, Daiichi-Sankyo
Robert A. Harrington(G/R) Merck/Schering Plough,CSL, GSK,Portola Pharmaceuticals, Regado, Sanofi-Aventis, AstraZeneca, Janssen,Bristol-Myers Squibb,Novartis,The Medicines Company (C/H/S)Merck/Schering, Amgen, Element Science, Gilead, MyoKardia, The Medicines Company
Gregg W. Stone -None
Harvey D. White (G/R) AstraZeneca, Sanofi Aventis, Eli Lilly, NIH, GlaxoSmithKline, Omthera Pharm. Pfizer NZ, Elsai Inc., DalGen
Planning Committee
Arielle Gelardi (Planner)
(S) Cardiovascular Research Foundation
ACTIVITY SPONSORSHIP AND SUPPORT
This program is sponsored by the Cardiovascular Research Foundation. It is supported through an educational grant from CHIESI USA, Inc. and was developed without influence from commercial supporters.
HOW TO RECEIVE CME CREDIT
To obtain CME credit for this activity, participants must review all CME information, view all presentations in their entirety, and complete the Activity Evaluation Form. If you have any questions, please contact Arielle Gelardi at agelardi@crf.org